Long-term follow-up for SKG0106 in wet AMD
Part of Eyes & vision clinical trials.
This study follows people who already received the SKG0106 injection in a previous trial for wet age-related macular degeneration (nAMD). It checks how they are doing over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous SKG0106 study and received the SKG0106 injection.
- You must agree to sign a consent form after understanding the study.
- You must be willing to follow the study plan and attend all visits.
- Your doctor must not think that being in this study is unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.